S&P 500   5,078.18 (+0.17%)
DOW   38,972.41 (-0.25%)
QQQ   437.60 (+0.24%)
AAPL   182.63 (+0.81%)
MSFT   407.48 (-0.01%)
META   487.05 (+1.10%)
GOOGL   138.88 (+0.95%)
AMZN   173.54 (-0.68%)
TSLA   199.73 (+0.17%)
NVDA   787.01 (-0.49%)
NIO   5.78 (+2.30%)
AMD   178.00 (+1.13%)
BABA   77.68 (+1.53%)
T   16.84 (+1.39%)
F   12.01 (+0.50%)
MU   91.85 (+2.67%)
CGC   3.53 (+1.73%)
GE   153.99 (-0.50%)
DIS   109.45 (+1.64%)
AMC   4.81 (+7.86%)
PFE   26.89 (-1.07%)
PYPL   60.16 (+1.40%)
XOM   104.03 (-0.21%)
S&P 500   5,078.18 (+0.17%)
DOW   38,972.41 (-0.25%)
QQQ   437.60 (+0.24%)
AAPL   182.63 (+0.81%)
MSFT   407.48 (-0.01%)
META   487.05 (+1.10%)
GOOGL   138.88 (+0.95%)
AMZN   173.54 (-0.68%)
TSLA   199.73 (+0.17%)
NVDA   787.01 (-0.49%)
NIO   5.78 (+2.30%)
AMD   178.00 (+1.13%)
BABA   77.68 (+1.53%)
T   16.84 (+1.39%)
F   12.01 (+0.50%)
MU   91.85 (+2.67%)
CGC   3.53 (+1.73%)
GE   153.99 (-0.50%)
DIS   109.45 (+1.64%)
AMC   4.81 (+7.86%)
PFE   26.89 (-1.07%)
PYPL   60.16 (+1.40%)
XOM   104.03 (-0.21%)
S&P 500   5,078.18 (+0.17%)
DOW   38,972.41 (-0.25%)
QQQ   437.60 (+0.24%)
AAPL   182.63 (+0.81%)
MSFT   407.48 (-0.01%)
META   487.05 (+1.10%)
GOOGL   138.88 (+0.95%)
AMZN   173.54 (-0.68%)
TSLA   199.73 (+0.17%)
NVDA   787.01 (-0.49%)
NIO   5.78 (+2.30%)
AMD   178.00 (+1.13%)
BABA   77.68 (+1.53%)
T   16.84 (+1.39%)
F   12.01 (+0.50%)
MU   91.85 (+2.67%)
CGC   3.53 (+1.73%)
GE   153.99 (-0.50%)
DIS   109.45 (+1.64%)
AMC   4.81 (+7.86%)
PFE   26.89 (-1.07%)
PYPL   60.16 (+1.40%)
XOM   104.03 (-0.21%)
S&P 500   5,078.18 (+0.17%)
DOW   38,972.41 (-0.25%)
QQQ   437.60 (+0.24%)
AAPL   182.63 (+0.81%)
MSFT   407.48 (-0.01%)
META   487.05 (+1.10%)
GOOGL   138.88 (+0.95%)
AMZN   173.54 (-0.68%)
TSLA   199.73 (+0.17%)
NVDA   787.01 (-0.49%)
NIO   5.78 (+2.30%)
AMD   178.00 (+1.13%)
BABA   77.68 (+1.53%)
T   16.84 (+1.39%)
F   12.01 (+0.50%)
MU   91.85 (+2.67%)
CGC   3.53 (+1.73%)
GE   153.99 (-0.50%)
DIS   109.45 (+1.64%)
AMC   4.81 (+7.86%)
PFE   26.89 (-1.07%)
PYPL   60.16 (+1.40%)
XOM   104.03 (-0.21%)

Travere Therapeutics (TVTX) Short Interest Ratio & Short Volume

$8.31
+0.29 (+3.62%)
(As of 02/27/2024 ET)

Travere Therapeutics Short Interest Data

Current Short Volume
9,930,000 shares
Previous Short Volume
9,710,000 shares
Change Vs. Previous Month
+2.27%
Dollar Volume Sold Short
$88.67 million
Short Interest Ratio / Days to Cover
6.3
Last Record Date
January 31, 2024
Outstanding Shares
76,100,000 shares
Percentage of Shares Shorted
13.05%
Today's Trading Volume
1,771,172 shares
Average Trading Volume
1,296,410 shares
Today's Volume Vs. Average
137%
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling Travere Therapeutics ?

Sign up to receive the latest short interest report for Travere Therapeutics and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

TVTX Short Interest Over Time

TVTX Days to Cover Over Time

TVTX Percentage of Float Shorted Over Time


Travere Therapeutics Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
1/31/20249,930,000 shares $88.67 million +2.3%N/A6.3 $8.93
1/15/20249,710,000 shares $92.54 million -2.1%N/A5.8 $9.53
12/31/20239,920,000 shares $89.18 million +2.9%N/A5.9 $8.99
12/15/20239,640,000 shares $83.48 million -3.1%N/A5.8 $8.66
11/30/20239,950,000 shares $62.49 million -6.7%N/A5 $6.28
11/15/202310,660,000 shares $65.77 million +21.0%N/A5.9 $6.17
10/31/20238,810,000 shares $57.09 million +0.5%N/A5.2 $6.48
10/15/20238,770,000 shares $62.27 million +4.2%N/A5.6 $7.10
9/30/20238,420,000 shares $75.27 million -6.9%N/A5.8 $8.94
9/15/20239,040,000 shares $123.76 million +5.7%N/A6.7 $13.69
8/31/20238,550,000 shares $122.09 million +5.6%N/A8.3 $14.28
8/15/20238,100,000 shares $123.12 million +0.4%N/A7.6 $15.20
7/31/20238,070,000 shares $138.72 million -2.7%N/A7.3 $17.19
7/15/20238,290,000 shares $126.92 million -2.5%N/A6.5 $15.31
6/30/20238,500,000 shares $130.56 million +11.0%N/A6.3 $15.36
6/15/20237,660,000 shares $131.75 million +4.9%N/A5.4 $17.20
5/31/20237,300,000 shares $130.60 million -3.2%N/A5.4 $17.89
5/15/20237,540,000 shares $123.20 million -4.1%N/A4.7 $16.34
4/30/20237,860,000 shares $169.54 million -3.7%N/A4.7 $21.57
4/15/20238,160,000 shares $165.81 million -4.5%N/A5.6 $20.32
3/31/20238,540,000 shares $192.06 million +14.8%N/A5.7 $22.49
3/15/20237,440,000 shares $158.25 million -1.6%N/A5.4 $21.27
2/28/20237,560,000 shares $167.53 million +9.9%N/A5.7 $22.16
2/15/20236,880,000 shares $138.43 million -7.7%N/A5.8 $20.12
1/31/20237,450,000 shares $166.88 million -0.9%N/A8.8 $22.40
1/15/20237,520,000 shares $152.81 million -10.3%N/A9.1 $20.32
12/30/20228,380,000 shares $176.23 million +3.1%N/A10 $21.03
12/15/20228,130,000 shares $150.41 million -1.2%N/A9.7 $18.50
11/30/20228,230,000 shares $165.67 million +5.9%N/A10.6 $20.13
11/15/20227,770,000 shares $167.13 million -1.2%N/A10.4 $21.51
10/31/20227,860,000 shares $170.40 million +23.0%13.0%10.9 $21.68
10/15/20226,390,000 shares $132.15 million -6.2%10.6%8.4 $20.68
9/30/20226,810,000 shares $167.80 million +3.0%11.3%10.3 $24.64
9/15/20226,610,000 shares $179.79 million -0.5%11.0%9.9 $27.20
8/31/20226,640,000 shares $177.69 million -10.2%11.1%9 $26.76
8/15/20227,390,000 shares $211.28 million +7.9%12.3%9.7 $28.59
7/31/20226,850,000 shares $161.25 million +2.4%11.5%7.9 $23.54
7/15/20226,690,000 shares $163.97 million -5.0%11.2%8.4 $24.51
6/30/20227,040,000 shares $170.58 million +6.2%11.8%8.6 $24.23
6/15/20226,630,000 shares $160.18 million -10.4%11.1%8 $24.16













TVTX Short Interest - Frequently Asked Questions

What is Travere Therapeutics' current short interest?

Short interest is the volume of Travere Therapeutics shares that have been sold short but have not yet been covered or closed out. As of January 31st, traders have sold 9,930,000 shares of TVTX short. Learn More on Travere Therapeutics' current short interest.

What is a good short interest ratio for Travere Therapeutics?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. TVTX shares currently have a short interest ratio of 6.0. Learn More on Travere Therapeutics's short interest ratio.

Which institutional investors are shorting Travere Therapeutics?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Travere Therapeutics: Barclays PLC, Parallax Volatility Advisers L.P., Citadel Advisors LLC, Capstone Investment Advisors LLC, UBS Group AG, Concourse Financial Group Securities Inc., and Wolverine Asset Management LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Is Travere Therapeutics' short interest increasing or decreasing?

Travere Therapeutics saw a increase in short interest in January. As of January 31st, there was short interest totaling 9,930,000 shares, an increase of 2.3% from the previous total of 9,710,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does Travere Therapeutics' short interest compare to its competitors?

Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Travere Therapeutics: Calliditas Therapeutics AB (publ) (0.02%), Astria Therapeutics, Inc. (5.25%), Mineralys Therapeutics, Inc. (4.27%), COMPASS Pathways plc (5.74%), Biomea Fusion, Inc. (33.47%), Ocular Therapeutix, Inc. (4.99%), Savara Inc (4.21%), Fulcrum Therapeutics, Inc. (5.47%), Phathom Pharmaceuticals, Inc. (32.43%), Bicycle Therapeutics plc (12.58%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($4.48 billion), General Motors ($3.85 billion), Charter Communications, Inc. ($3.38 billion), Occidental Petroleum Co. ($3.00 billion), Super Micro Computer, Inc. ($2.66 billion), Tractor Supply ($2.37 billion), Coinbase Global, Inc. ($2.25 billion), Moderna, Inc. ($2.11 billion), Royal Caribbean Cruises Ltd. ($2.06 billion), and Floor & Decor Holdings, Inc. ($1.67 billion). View all of the most shorted stocks.

What does it mean to sell short Travere Therapeutics stock?

Short selling TVTX is an investing strategy that aims to generate trading profit from Travere Therapeutics as its price is falling. TVTX shares are trading up $0.29 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Travere Therapeutics?

A short squeeze for Travere Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of TVTX, which in turn drives the price of the stock up even further.

How often is Travere Therapeutics' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including TVTX, twice per month. The most recent reporting period available is January, 31 2024.



More Short Interest Resources from MarketBeat

This page (NASDAQ:TVTX) was last updated on 2/27/2024 by MarketBeat.com Staff